Dr Kathleen Moore from the University of Oklahoma Health Sciences Center reviews key ovarian cancer abstracts from ESGO 2025.
She first highlights a multicenter study comparing three vs six cycles of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC). Results showed no improvement in surgical outcomes, pathologic response, progression-free survival (PFS), or overall survival with extended NACT, with BRCA status and ECOG performance status emerging as stronger predictors of survival.
Next, Dr Moore reviews a postprogression analysis of ATHENA-MONO, evaluating rucaparib vs placebo as maintenance therapy after frontline chemotherapy. At 4-year follow-up, rucaparib improved PFS2, extending chemo-free intervals in both the homologous recombination deficiency and intention-to-treat populations.
She then discusses KEYLYNK-001, which investigated pembrolizumab + chemotherapy, followed by olaparib maintenance, in BRCA1/2-nonmutated advanced EOC. Results showed a clinically meaningful PFS benefit in both patients with combined positive score ≥ 10 and the overall study population.
Finally, she highlights the MIRASOL study, which assessed quality-adjusted survival (Q-TWiST) with mirvetuximab soravtansine (MIRV) vs investigator’s choice chemotherapy. MIRV significantly extended symptom-free time (+2.41 months) and overall Q-TWiST (+2.29 months), highlighting its benefit in platinum-resistant ovarian cancer.
